Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 77,636 | 89,241 | 62,065 | 63,716 | 72,493 |
| Receivables | 1,590 | 893 | 477 | 7,264 | 1,496 |
| Inventories | 1,238 | 804 | 567 | 441 | 525 |
| TOTAL | $83,406 | $93,649 | $66,181 | $74,013 | $78,229 |
| Non-Current Assets | |||||
| PPE Net | 2,704 | 2,647 | 2,746 | 2,550 | 2,524 |
| TOTAL | $2,704 | $2,647 | $2,746 | $2,550 | $2,524 |
| Total Assets | $86,109 | $96,296 | $68,927 | $76,563 | $80,753 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,122 | 5,431 | 5,303 | 6,669 | 4,141 |
| Accrued Expenses | 5,750 | 4,722 | 4,474 | 3,996 | 3,705 |
| TOTAL | $15,813 | $15,168 | $13,331 | $14,218 | $11,062 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 4,942 | 5,016 | 3,554 | 3,554 | 3,216 |
| TOTAL | $53,696 | $54,693 | $51,672 | $46,964 | $38,805 |
| Total Liabilities | $69,509 | $69,861 | $65,003 | $61,183 | $49,867 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 91,647 | 89,723 | 82,958 | 82,946 | 81,444 |
| Common Shares | 91 | 90 | 83 | 82 | 81 |
| Retained earnings | -159,345 | -145,435 | -128,375 | -113,650 | -96,824 |
| TOTAL | $16,601 | $26,435 | $3,924 | $15,380 | $30,886 |
| Total Liabilities And Equity | $86,109 | $96,296 | $68,927 | $76,563 | $80,753 |